{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:50:04Z","timestamp":1791435004260,"version":"4.3.3"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004388","name":"Teva Branded Pharmeceutical Products R&D Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.psychres.2026.117452","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:39:29Z","timestamp":1788795569000},"page":"117452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Factors associated with rates of long-acting injectable antipsychotic use for schizophrenia: A subgroup analysis of the multinational ADVANCE study"],"prefix":"10.1016","volume":"366","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6405-3952","authenticated-orcid":false,"given":"Kelli R.","family":"Franzenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Suett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4782-8203","authenticated-orcid":false,"given":"Ayelet","family":"Yaari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3352-8480","authenticated-orcid":false,"given":"Sigal","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kameron","family":"Sedigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1351-003X","authenticated-orcid":false,"given":"Stephan","family":"Heres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Sajatovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.psychres.2026.117452_bib0001","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/07067437211055413","article-title":"Real-world utilization patterns of long-acting injectable antipsychotics in Canada: a retrospective study","volume":"67","author":"Agid","year":"2022","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117452_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2025.116460","article-title":"Oral versus long-acting injectable antipsychotics in schizophrenia spectrum disorders: a systematic review of patients' subjective experiences","volume":"348","author":"Aprile","year":"2025","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.psychres.2026.117452_bib0003","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12888-023-04928-0","article-title":"Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery","volume":"23","author":"Arango","year":"2023","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2026.117452_bib0004","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3390\/clinpract14040099","article-title":"Predictors of readmission in young adults with first-episode psychosis: a multicentric retrospective study with a 12-month follow-up","volume":"14","author":"Besana","year":"2024","journal-title":"Clin. Pract."},{"key":"10.1016\/j.psychres.2026.117452_bib0005","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/PPA.S251812","article-title":"Patients' Preference for long-acting injectable versus oral antipsychotics in schizophrenia: results from the patient-reported medication preference questionnaire","volume":"14","author":"Blackwood","year":"2020","journal-title":"Patient Prefer. Adherence"},{"issue":"6","key":"10.1016\/j.psychres.2026.117452_bib0006","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the Global Burden of Disease Study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psychres.2026.117452_bib0007","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/NDT.S326299","article-title":"Management of schizophrenia with long-acting injectable antipsychotic medications: an assessment of the educational needs of clinicians","volume":"18","author":"Citrome","year":"2022","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"10","key":"10.1016\/j.psychres.2026.117452_bib0008","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40263-025-01206-3","article-title":"Strategies for switching between oral postsynaptic antidopaminergic antipsychotics in patients with schizophrenia: a systematic review","volume":"39","author":"Correll","year":"2025","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.psychres.2026.117452_bib0009","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12888-022-03685-w","article-title":"The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach","volume":"22","author":"Correll","year":"2022","journal-title":"BMC Psychiatry"},{"issue":"suppl 3","key":"10.1016\/j.psychres.2026.117452_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.15032su1","article-title":"The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence","volume":"77","author":"Correll","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2026.117452_bib0011","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","article-title":"Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview","volume":"35","author":"Correll","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psychres.2026.117452_bib0012","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.2147\/NDT.S477674","article-title":"Introducing S.C.O.P.E.\u2122 (Schizophrenia Clinical Outcome Scenarios and Patient\u2013Provider Engagement), an interactive digital platform to educate healthcare professionals on schizophrenia care","volume":"20","author":"Correll","year":"2024","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.psychres.2026.117452_bib0013","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.24r15316","article-title":"The economic impact of cognitive impairment and negative symptoms in schizophrenia: a targeted literature review with a focus on outcomes relevant to health care decision-makers in the United States","volume":"85","author":"Correll","year":"2024","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2026.117452_bib0014","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1370\/afm.1615","article-title":"Shared decision making and motivational interviewing: achieving patient-centered care across the spectrum of health care problems","volume":"12","author":"Elwyn","year":"2014","journal-title":"Ann. Fam. Med."},{"issue":"4","key":"10.1016\/j.psychres.2026.117452_bib0015","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s12325-025-03130-w","article-title":"Survey on the initiation of aripiprazole once-monthly via a two-injection start in adult patients with schizophrenia: experience of European healthcare professionals","volume":"42","author":"Fagiolini","year":"2025","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.psychres.2026.117452_bib0016","article-title":"Attitudes driving regional differences in long-acting injectable antipsychotic utilization for schizophrenia among healthcare professionals, patients, and caregivers (ADVANCE): results from a multinational survey study","volume":"7","author":"Franzenburg","year":"2026","journal-title":"Schizophr. Bull. Open."},{"key":"10.1016\/j.psychres.2026.117452_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2025.1645328","article-title":"Experiences and perceptions of patients, caregivers, and healthcare professionals with long-acting injectable antipsychotics for the treatment of schizophrenia: qualitative results from the multinational ADVANCE study","volume":"16","author":"Franzenburg","year":"2025","journal-title":"Front. Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2026.117452_bib0018","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14656566.2023.2181073","article-title":"Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges","volume":"24","author":"Haddad","year":"2023","journal-title":"Expert. Opin. PharmacOther"},{"issue":"13","key":"10.1016\/j.psychres.2026.117452_bib0019","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1080\/14656566.2023.2228686","article-title":"Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches","volume":"24","author":"H\u00f8jlund","year":"2023","journal-title":"Expert. Opin. PharmacOther"},{"issue":"5","key":"10.1016\/j.psychres.2026.117452_bib0020","first-page":"HS1","article-title":"A practical review of long-acting injectable antipsychotics","volume":"49","author":"Hu","year":"2024","journal-title":"US Pharmacist"},{"issue":"5 Suppl 1","key":"10.1016\/j.psychres.2026.117452_bib0021","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1177\/088740341305805s04","article-title":"A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives","volume":"58","author":"Iyer","year":"2013","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117452_bib0022","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1177\/088740341305805s03","article-title":"A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part I\u2014patient perspectives","volume":"58","author":"Iyer","year":"2013","journal-title":"Can. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2026.117452_bib0023","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1007\/s40120-025-00838-3","article-title":"The use of long-acting injectables for people with schizophrenia: consensus panel recommendations for overcoming barriers and implementing treatment","volume":"14","author":"Kane","year":"2025","journal-title":"Neurol. Ther."},{"issue":"3","key":"10.1016\/j.psychres.2026.117452_bib0024","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18m12546","article-title":"Patients with early-phase schizophrenia will accept treatment with sustained-release medication (long-acting injectable antipsychotics): results from the recruitment phase of the PRELAPSE trial","volume":"80","author":"Kane","year":"2019","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.psychres.2026.117452_bib0025","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamapsychiatry.2020.2076","article-title":"Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial","volume":"77","author":"Kane","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2026.117452_bib0026","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12888-022-03846-x","article-title":"Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey","volume":"22","author":"Keenan","year":"2022","journal-title":"BMC Psychiatry"},{"issue":"9","key":"10.1016\/j.psychres.2026.117452_bib0027","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2026.117452_bib0028","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2026.117452_bib0029","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/13696998.2022.2157596","article-title":"Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries","volume":"26","author":"Kotzeva","year":"2023","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.psychres.2026.117452_bib0030","first-page":"917","article-title":"Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life","volume":"12","author":"Montemagni","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/j.psychres.2026.117452_bib0031","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/npr2.12435","article-title":"Barriers to long-acting injectable atypical antipsychotic use in Japan: insights from a comparative psychiatrist survey","volume":"44","author":"Oguchi","year":"2024","journal-title":"Neuropsychopharmacol. Rep."},{"key":"10.1016\/j.psychres.2026.117452_bib0032","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2147\/PPA.S520160","article-title":"Exploring patient, caregiver, and prescriber preferences for an injectable antipsychotic administered every 2 months for the maintenance treatment of schizophrenia: a multicenter qualitative interview study conducted in Europe","volume":"19","author":"Pappa","year":"2025","journal-title":"Patient Prefer. Adherence"},{"issue":"8","key":"10.1016\/j.psychres.2026.117452_bib0033","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s40263-016-0350-7","article-title":"Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia","volume":"30","author":"Parellada","year":"2016","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.psychres.2026.117452_bib0034","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel","year":"2014","journal-title":"P. T."},{"issue":"1","key":"10.1016\/j.psychres.2026.117452_bib0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12888-020-02530-2","article-title":"Attitudes of European physicians towards the use of long-acting injectable antipsychotics","volume":"20","author":"Patel","year":"2020","journal-title":"BMC Psychiatry"},{"issue":"10","key":"10.1016\/j.psychres.2026.117452_bib0036","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/0269881109104882","article-title":"Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years","volume":"24","author":"Patel","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2026.117452_bib0037","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/1471-244X-13-261","article-title":"Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia","volume":"13","author":"Potkin","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2026.117452_bib0038","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3371\/CSRP.PORI.050614","article-title":"A pilot study of cultural\/racial differences in patient perspectives on long-acting injectable antipsychotics for the treatment of schizophrenia","volume":"10","author":"Potkin","year":"2017","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"issue":"4","key":"10.1016\/j.psychres.2026.117452_bib0039","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4103\/0019-5545.58304","article-title":"The story of antipsychotics: past and present","volume":"51","author":"Ramachandraiah","year":"2009","journal-title":"Indian J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.psychres.2026.117452_bib0040","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.schres.2006.11.015","article-title":"The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia","volume":"90","author":"Remington","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2026.117452_bib0041","series-title":"Annual Psych Congress Elevate, May 28\u201331, 2025","article-title":"Enabling conversations about long-acting injectable antipsychotics among HCPs, patients, and caregivers with the long-acting injectable antipsychotics: conversations and Resources for Education (LAI-CARE) website","author":"Robinson","year":"2025"},{"issue":"4","key":"10.1016\/j.psychres.2026.117452_bib0042","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/17425255.2023.2220962","article-title":"Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations","volume":"19","author":"Schoretsanitis","year":"2023","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"issue":"1\u20133","key":"10.1016\/j.psychres.2026.117452_bib0043","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","article-title":"Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia","volume":"169","author":"Schreiner","year":"2015","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.psychres.2026.117452_bib0044","doi-asserted-by":"crossref","first-page":"232","DOI":"10.9740\/mhc.2022.08.232","article-title":"Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners","volume":"12","author":"Schwartz","year":"2022","journal-title":"Ment. Health Clin."},{"issue":"11","key":"10.1016\/j.psychres.2026.117452_bib0045","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1007\/s12325-018-0786-x","article-title":"Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics","volume":"35","author":"Shah","year":"2018","journal-title":"Adv. Ther."},{"issue":"8","key":"10.1016\/j.psychres.2026.117452_bib0046","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","article-title":"Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial","volume":"72","author":"Subotnik","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2026.117452_bib0047","doi-asserted-by":"crossref","DOI":"10.1111\/appy.12393","article-title":"Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region","volume":"12","author":"Tang","year":"2020","journal-title":"Asia Pac. Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2026.117452_bib0048","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","article-title":"A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia","volume":"168","author":"Tiihonen","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2026.117452_bib0049","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.psychres.2026.117452_bib0050","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12888-025-06565-1","article-title":"Clinician differences in attitudes and perceptions on the use of long-acting injectable antipsychotic agents in treating patients with schizophrenia: results from the US DECIDE Survey","volume":"25","author":"Velligan","year":"2025","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psychres.2026.117452_bib0051","doi-asserted-by":"crossref","DOI":"10.1177\/20451253241257062","article-title":"Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: a systematic review and meta-analysis","volume":"14","author":"Vita","year":"2024","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.psychres.2026.117452_bib0052","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.euroneuro.2024.03.003","article-title":"Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: systematic review and network meta-analysis","volume":"83","author":"Wang","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2026.117452_bib0053","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.903156","article-title":"Antipsychotic drug development: from historical evidence to fresh perspectives","volume":"13","author":"Weston-Green","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.psychres.2026.117452_bib0054","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2147\/NDT.S369494","article-title":"Understanding the health system conditions affecting the use of long-acting injectable antipsychotics in the treatment of schizophrenia in clinical practice: a US healthcare provider survey","volume":"18","author":"Zhdanava","year":"2022","journal-title":"Neuropsychiatr. Dis. Treat."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126005123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178126005123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:12:29Z","timestamp":1791432749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178126005123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":54,"alternative-id":["S0165178126005123"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117452","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with rates of long-acting injectable antipsychotic use for schizophrenia: A subgroup analysis of the multinational ADVANCE study","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2026.117452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117452"}}